Hoogwerf相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

Real-World Glycemic Lowering Effectiveness of Linagliptin Among Adults with Type 2 Diabetes by Age, Renal Function, and Race

利格列汀在2型糖尿病成人患者中真实世界中的降血糖疗效（按年龄、肾功能和种族划分）

期刊:Diabetes Therapy

影响因子:2.6

doi:10.1007/s13300-020-00841-x

Hoogwerf, Byron J; MacKenzie, Michele; Sealls, Whitney; Cordova, Jeanine; Gandhi, Pranav

发表日期：2020

文献求助收藏

The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes

基础胰岛素培格列丙与甘精胰岛素对糖尿病患者 NMR 脂蛋白颗粒和 MRI 肝脏脂肪含量的影响

期刊:Cardiovascular Diabetology

影响因子:8.5

doi:10.1186/s12933-017-0555-1

Trevor J Orchard, Bertrand Cariou, Margery A Connelly, James D Otvos, Shuyu Zhang, Caryl J Antalis, Tibor Ivanyi, Byron J Hoogwerf

发表日期：2017

文献求助收藏

Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis

基础胰岛素培格列普与对照胰岛素治疗1型或2型糖尿病患者的主要不良心血管事件：一项荟萃分析

期刊:Cardiovascular Diabetology

影响因子:10.6

doi:10.1186/s12933-016-0393-6

Hoogwerf, Byron J; Lincoff, A Michael; Rodriguez, Angel; Chen, Lei; Qu, Yongming

免疫/内分泌

发表日期：2016

文献求助收藏

Risk factors for 30-day readmission following hypoglycemia-related emergency room and inpatient admissions

低血糖相关急诊和住院治疗后30天内再入院的风险因素

期刊:Bmj Open Diabetes Research & Care

影响因子:4.1

doi:10.1136/bmjdrc-2015-000160

Emons, M F; Bae, J P; Hoogwerf, B J; Kindermann, S L; Taylor, R J; Nathanson, B H

发表日期：2016

文献求助收藏

Medication utilization patterns among type 2 diabetes patients initiating Exenatide BID or insulin glargine: a retrospective database study

2 型糖尿病患者开始使用艾塞那肽每日两次或甘精胰岛素时的用药模式：一项回顾性数据库研究

期刊:BMC Endocrine Disorders

影响因子:3.3

doi:10.1186/1472-6823-13-20

Pawaskar, Manjiri; Bonafede, Machaon; Johnson, Barbara; Fowler, Robert; Lenhart, Gregory; Hoogwerf, Byron

免疫/内分泌

发表日期：2013

文献求助收藏

Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis

艾塞那肽每周一次、胰岛素和吡格列酮治疗2型糖尿病的健康和经济结果：一项模拟分析

期刊:Vascular Health and Risk Management

影响因子:2.8

doi:10.2147/VHRM.S28744

Gaebler, Julia A; Soto-Campos, Gerardo; Alperin, Peter; Cohen, Marc; Blickensderfer, Amy; Wintle, Matthew; Maggs, David; Hoogwerf, Byron; Han, Jenny; Pencek, Richard; Peskin, Barbara

免疫/内分泌

发表日期：2012

文献求助收藏

Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy

在基础胰岛素治疗基础上加用艾塞那肽（每日两次）治疗2型糖尿病：临床研究和实用治疗方法

期刊:International Journal of Clinical Practice

影响因子:2.4

doi:10.1111/ijcp.12032

Tobin, G S; Cavaghan, M K; Hoogwerf, B J; McGill, J B

免疫/内分泌

发表日期：2012

文献求助收藏

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

艾塞那肽每日两次给药的心血管安全性：一项针对2型糖尿病患者的对照临床试验的综合分析

期刊:Cardiovascular Diabetology

影响因子:10.6

doi:10.1186/1475-2840-10-22

Ratner, Robert; Han, Jenny; Nicewarner, Dawn; Yushmanova, Irina; Hoogwerf, Byron J; Shen, Larry

发表日期：2011

文献求助收藏

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database

接受胰高血糖素样肽-1 (GLP-1) 受体激动剂艾塞那肽每日两次或其他降糖疗法治疗的 2 型糖尿病患者发生心血管疾病事件的风险：LifeLink 数据库的回顾性分析

doi:10.2337/dc10-1393

Best, Jennie H; Hoogwerf, Byron J; Herman, William H; Pelletier, Elise M; Smith, Daniel B; Wenten, Made; Hussein, Mohamed A

心血管疾病

发表日期：2011

文献求助收藏

Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study

艾塞那肽对2型糖尿病患者心率和血压的影响：一项双盲、安慰剂对照、随机试点研究

期刊:Cardiovascular Diabetology

影响因子:10.6

doi:10.1186/1475-2840-9-6

Gill, Anne; Hoogwerf, Byron J; Burger, Jude; Bruce, Simon; Macconell, Leigh; Yan, Ping; Braun, Daniel; Giaconia, Joseph; Malone, James

发表日期：2010

文献求助收藏